Anzeige
Mehr »
Samstag, 16.05.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CN5Q | ISIN: US91864C1071 | Ticker-Symbol: 2AB
Tradegate
15.05.26 | 16:52
0,600 Euro
+2,56 % +0,015
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BARINTHUS BIOTHERAPEUTICS PLC ADR Chart 1 Jahr
5-Tage-Chart
BARINTHUS BIOTHERAPEUTICS PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
0,5750,58513:04
0,5500,62515.05.

Aktuelle News zur BARINTHUS BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01.05.Barinthus BioTherapeutics GAAP EPS of -$0.1413
30.04.Barinthus in Green on Bringing Out Quarterly Numbers1
30.04.Barinthus Biotherapeutics: Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments149Proposed combination with Clywedog Therapeutics Inc. ("Clywedog") progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with...
► Artikel lesen
30.04.Barinthus Biotherapeutics plc. - 10-Q, Quarterly Report-
30.04.Barinthus Biotherapeutics plc. - 8-K, Current Report1
22.04.Barinthus Biotherapeutics plc. - 8-K, Current Report-
BARINTHUS BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
31.03.Barinthus Biotherapeutics plc. - 8-K, Current Report-
13.03.Barinthus BioTherapeutics GAAP EPS of -$1.641
13.03.Barinthus Biotherapeutics plc. - 10-K, Annual Report2
13.03.Barinthus Biotherapeutics plc. - 8-K, Current Report2
23.02.Barinthus Biotherapeutics plc. - 8-K, Current Report3
06.01.Barinthus Biotherapeutics plc. - 8-K, Current Report-
10.12.25Barinthus Biotherapeutics plc. - 8-K, Current Report-
07.11.25Barinthus Biotherapeutics: Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments208Single ascending dose data readout for VTP-1000 expected before the end of 2025Enrollment advancing in multiple ascending dose part of the AVALON trial; data expected in the second half of 2026Proposed...
► Artikel lesen
24.10.25ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics204SAN DIEGO, Oct. 24, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry...
► Artikel lesen
30.09.25Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases486GERMANTOWN, MD and ALTRINCHAM, UK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates...
► Artikel lesen
09.06.25Barinthus Biotherapeutics plc: Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025325OXFORD, GB AND GERMANTOWN, MD / ACCESS Newswire / June 9, 2025 / Barinthus Biotherapeutics plc announced that Bill Enright, CEO, will be presenting at the Investor Summit Virtual taking place on June...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1